Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SAMEH E MIKHAIL

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1447455720
CMS profile
404094
Location
COLUMBUS, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$44,461.80

128 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SAMEH E MIKHAIL

NPI 1447455720 · CMS profile ID 404094

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

COLUMBUS, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447455720?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SAMEH E MIKHAIL, NPI 1447455720, CMS profile ID 404094. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447455720?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). SAMEH E MIKHAIL, NPI 1447455720, CMS profile ID 404094. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447455720?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
SAMEH E MIKHAIL, NPI 1447455720, CMS profile ID 404094, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1447455720?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

128 matching records · $44,461.80 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 128 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–128 of 128.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ARRAY BIOPHARMA INC $0.1604/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229052233 CMS
AstraZeneca Pharmaceuticals LP $132.7904/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206694980 CMS
GlaxoSmithKline, LLC. $24.8604/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191114326 CMS
Daiichi Sankyo Inc. $23.7903/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197050643 CMS
Eisai Inc. $29.5503/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244510535 CMS
E.R. Squibb & Sons, L.L.C. $14.5503/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184811755 CMS
Daiichi Sankyo Inc. $25.2303/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197052609 CMS
TAIHO ONCOLOGY, INC. $25.8803/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211410608 CMS
Geron Corporation $32.5803/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238891570 CMS
Blueprint Medicines Corporation $24.3503/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235819470 CMS
ABBVIE INC. $33.9903/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203082585 CMS
AstraZeneca Pharmaceuticals LP $135.6302/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206710055 CMS
Bayer Healthcare Pharmaceuticals Inc. $81.9102/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225653952 CMS
AstraZeneca Pharmaceuticals LP $18.7702/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206856010 CMS
Iovance Biotherapeutics, Inc. $14.6802/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251396903 CMS
Geron Corporation $34.0002/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238891568 CMS
SpringWorks Therapeutics, Inc. $35.2002/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232165570 CMS
Adaptive Biotechnologies Corporation $16.6802/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1254940786 CMS
Merck Sharp & Dohme LLC $15.2702/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238319882 CMS
Merck Sharp & Dohme LLC $32.1502/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238367863 CMS
Janssen Biotech, Inc. $25.6001/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174327995 CMS
Regeneron Healthcare Solutions, Inc. $24.1801/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212990322 CMS
JAZZ PHARMACEUTICALS INC. $4,272.0001/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234298934 CMS
EMD Serono, Inc. $16.5001/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236919317 CMS
Eisai Inc. $29.2801/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244510533 CMS
ARRAY BIOPHARMA INC $30.0001/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231335281 CMS
Janssen Biotech, Inc. $18.5401/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174328082 CMS
Octapharma USA, Inc. $24.7401/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1245080831 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $14,196.72 51
PY2020 $5,611.61 51
PY2021 $15,984.76 72
PY2022 $30,820.76 62
PY2023 $5,843.07 72
PY2024 $18,056.07 105
PY2025 $44,461.80 128

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $163,495.46 22
PY2024 Principal investigator $180,272.48 11
PY2023 Principal investigator $56,968.59 53
PY2022 Principal investigator $22,408.99 28
PY2021 Principal investigator $2,779.87 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

22 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $3,000.00 10/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228707133
Principal investigator 1 PFIZER INC. $3,000.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228706961
Principal investigator 1 PFIZER INC. $3,000.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228707131
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,000.00 08/27/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
Fruquintinib No dispute reported 06/30/2026 1223284637
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,072.00 08/27/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
Fruquintinib No dispute reported 06/30/2026 1223284639
Principal investigator 1 Amgen Inc. $5,000.00 08/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTION LLC
A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation No dispute reported 06/30/2026 1246647982
Principal investigator 1 PFIZER INC. $3,000.00 07/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228773028
Principal investigator 1 PFIZER INC. $5,200.00 06/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228790999
Principal investigator 1 PFIZER INC. $3,000.00 06/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228790324
Principal investigator 1 PFIZER INC. $3,000.00 06/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228791550
Principal investigator 1 PFIZER INC. $43,996.68 05/15/2025 Non-covered Recipient Entity
Zangmeister Cancer Center
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228754278
Principal investigator 1 PFIZER INC. $10,940.00 05/15/2025 Non-covered Recipient Entity
Zangmeister Cancer Center
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228755913
Principal investigator 1 PFIZER INC. $43,996.68 05/12/2025 Non-covered Recipient Entity
Zangmeister Cancer Center
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228757186
Principal investigator 1 PFIZER INC. $10,940.00 05/12/2025 Non-covered Recipient Entity
Zangmeister Cancer Center
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228759525
Principal investigator 1 PFIZER INC. $3,000.00 05/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228764840
Principal investigator 1 PFIZER INC. $3,000.00 05/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228784181
Principal investigator 1 PFIZER INC. $3,000.00 03/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228797535
Principal investigator 1 PFIZER INC. $3,000.00 02/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228799078
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $77.80 01/15/2025 Non-covered Recipient Entity
Mark H. Zangmeister Cancer Center
A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2D), and Efficacy of Lurbinectedin Monotherapy in Pediatric Participants With Previously Treated Solid Tumors Followed by Expansion to Assess Efficacy and Safety in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma. No dispute reported 06/30/2026 1233740436
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $77.80 01/15/2025 Non-covered Recipient Entity
Mark H. Zangmeister Cancer Center
A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2D), and Efficacy of Lurbinectedin Monotherapy in Pediatric Participants With Previously Treated Solid Tumors Followed by Expansion to Assess Efficacy and Safety in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma. No dispute reported 06/30/2026 1233740438
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $194.50 01/15/2025 Non-covered Recipient Entity
Mark H. Zangmeister Cancer Center
A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2D), and Efficacy of Lurbinectedin Monotherapy in Pediatric Participants With Previously Treated Solid Tumors Followed by Expansion to Assess Efficacy and Safety in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma. No dispute reported 06/30/2026 1233740440
Principal investigator 1 PFIZER INC. $3,000.00 01/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228802293